- Home
- FT vs CRVS Comparison
FT vs CRVS Comparison
Compare FT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- CRVS
- Stock Information
- Founded
- FT 1988
- CRVS 2014
- Country
- FT United States
- CRVS United States
- Employees
- FT N/A
- CRVS N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- CRVS Health Care
- Exchange
- FT Nasdaq
- CRVS Nasdaq
- Market Cap
- FT 185.7M
- CRVS 516.0M
- IPO Year
- FT N/A
- CRVS 2016
- Fundamental
- Price
- FT $7.29
- CRVS $5.10
- Analyst Decision
- FT
- CRVS Strong Buy
- Analyst Count
- FT 0
- CRVS 5
- Target Price
- FT N/A
- CRVS $12.38
- AVG Volume (30 Days)
- FT 63.0K
- CRVS 1.7M
- Earning Date
- FT 01-01-0001
- CRVS 11-12-2024
- Dividend Yield
- FT 7.85%
- CRVS N/A
- EPS Growth
- FT N/A
- CRVS N/A
- EPS
- FT N/A
- CRVS N/A
- Revenue
- FT N/A
- CRVS N/A
- Revenue This Year
- FT N/A
- CRVS N/A
- Revenue Next Year
- FT N/A
- CRVS N/A
- P/E Ratio
- FT N/A
- CRVS N/A
- Revenue Growth
- FT N/A
- CRVS N/A
- 52 Week Low
- FT $5.97
- CRVS $1.30
- 52 Week High
- FT $7.23
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FT 40.30
- CRVS 36.16
- Support Level
- FT $7.19
- CRVS $4.93
- Resistance Level
- FT $7.35
- CRVS $6.47
- Average True Range (ATR)
- FT 0.09
- CRVS 0.40
- MACD
- FT 0.00
- CRVS 0.06
- Stochastic Oscillator
- FT 43.75
- CRVS 29.74
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).